AstraZeneca

Clinical Study Results Posting Template

Template completed by:	**Agrita Hartmane**	
Template content reviewed		Select from list
Study posting approved by:		

Posting Results:

☐ Hypothesis-testing study in any indication

☐ Study in patients with a serious or life-threatening disease or condition

☒ Non-interventional study with an approved product.

1. TITLES AND BACKGROUND INFORMATION

- Protocol ID: D5890L00031(NIS-RLVSYM-2007/1)
- Secondary ID: SYMCO
- Official Title: NIS for patients using Symbicort® Turbuhaler®for Maintenance and Reliever therapy in a Single Inhaler
- Finished Product: Symbicort
- Active Ingredient: Budesonid/Formoterol
- Study Phase: NA
- Study Status: Completed
- Select Indication:



2. KEY STUDY DATES

- Study Start Date: 01 October 2007

  Database Lock: 30 June 2007

- Approval Date: 28 September 2007

3. OBJECTIVES

Primary objective of the non-interventional study is to investigate the extent of Symbicort use and to assess the effect of Symbicort maintenance and reliever therapy in a single inhaler on the received daily dose of inhaled glucocorticosteroids

4. METHODS

Descriptive statistics and plots, illustrating different aspects of the daily use of Symbicort.

5. RESULTS

Average GCS dose received by reliever inhalation at 2nd visit 112 mcg/d (0,7 inhalations) and 3rd visit 96 mcg/d (0,6 inhalations). Number of daily reliever inhalations is limited and days with total 8/12 inhalations are seldom.

6. REFERENCE : None

Citation:

PMID: